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INTRODUCTION
The medical device sector is the fastest growing sector 
among its own category. Whenever a new medical device is 
developed, before it can be sold and supplied to the patient, it 
has to have a license from appropriate competent authorities 
worldwide. Since the beginning of 1980s, the regulatory 
world for medical devices has changed dramatically. From 
few countries, there are now 60-65 countries which have 
implemented regulation for medical devices or will soon 
implement the regulation for medical devices.[1]
First of all, I akin to initiate with what does the Medical 
Device Harmonization and Medical Device actually mean?
Medical device harmonization
“To encourage convergence in regulatory practices 
related to ensuring the safety, effectiveness/performance 
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and quality of medical devices, promoting technological 
innovation and facilitating international trade.”[2]
Harmonization
“To bring into agreement or harmony.”
Harmony*
“Agreement in feeling or opinion.”
(*According  to  the  American  Heritage  College 
Dictionary, 3rd edition; 2000)
Medical device sector is one of the most complex and 
challenging business segments of the healthcare industry 
with close collaboration between science and engineering. 
The term “medical devices” includes everything from 
highly sophisticated computerized medical equipment 
down to simple wooden tongue depressors. The intended 
primary mode of action of a medical device on the human 
body, in contrast with that of medicinal products, is not 
metabolic, immunological, or pharmacological.[2] But 
overall in broad sense we can describe medical devices as 
any instrument, apparatus, implement, machine, appliance, 
implant, in vitro reagent or calibrator, software, material or 
other similar or related article intended by the manufacturer 
to be used, alone or in combination, for human beings for 
one or more of the specific purposes of
•  Diagnosis, prevention, monitoring, treatment, or 
alleviation of disease
•  Diagnosis, monitoring, treatment, alleviation of or 
compensation for an injury
•  Investigation, replacement, modification, or support 
of the anatomy or of a physiological process
•  Supporting or sustaining life
•  Control of conception
•  Disinfection of medical devices
•  Providing information for medical purposes by 
means of in vitro examination of specimens derived 
from the human body and which does not achieve its 
primary intended action in or on the human body by 
pharmacological, immunological, or metabolic means, 
but which may be assisted in its function by such means.  [3]
PRESENT SCENARIO OF THE MEDICAL DEVICE 
SECTOR IN ASIA
Despite the fact that Asia has 60% of the world population 
providing large market potential, Asian healthcare 
expenditure constitutes only 15% of the global healthcare 
expenditure. In 2007, the total global healthcare expenditure 
was at US$ 4.981 trillion. With a growth rate of 6.2% as 
shown in Figure 1, the total healthcare expenditure of Asia 
was US$ 791.7 billion in 2008.[4]
While some parts of Asia are experiencing a high population 
growth, other countries such as Japan and China are facing 
the problem of accelerated ageing population. For instance, 
Japan is estimated to have 22.0% of its population above 
65 years by 2012 as compared to 20.6% in 2007 [Figure 2]. 
With the current Asian lifestyle, the prevalence of chronic 
diseases such as diabetes, cancer, obesity and cardiovascular 
diseases has increased significantly. Other diseases that 
threaten the region include auto-immune diseases, infectious 
diseases, and neurological disorders. Accelerated ageing 
population and the increasing prevalence of chronic diseases 
are the key drivers that contribute toward the increase in total 
healthcare expenditure on medical devices in the region.[4]
Realizing the importance of disease prevention, the 
Asian governments invested billions of dollars annually 
to improve their healthcare infrastructure. For instance, 
the Ninth Malaysia Plan (2006-2010) is to work “toward 
achieving better health through consolidation of services” 
whereby emphasis has been placed on sustainability, 
upgrading, and maintenance of existing facilities and 
Figure 1: Total healthcare expenditure 2007-2008
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equipment, and improving the quality of healthcare. China 
announced its Healthy China 2020 plan in January this 
year, which aims to provide safe, effective, convenient, and 
low-cost public health and basic medical care to both rural 
and urban citizens by 2020.[4] Some key goals of the plan 
include making public medical institutions “nonprofit,” 
reducing the involvement of hospitals in the sale of drugs, 
increasing the role and responsibility of government, and 
establishing a basic medical care network for all Chinese 
citizens. High participation from private healthcare 
providers in developed countries in Asia promotes 
healthcare expenditure. For instance, Taiwan has fairly high 
participation of private healthcare, which contributes 65% 
of Taiwan’s total hospital beds. Private involvement has 
enabled efficient healthcare delivery to the people, which 
could be clearly seen in the case of Taiwan. This private 
participation was driven by Taiwanese comprehensive 
National Health Insurance scheme, which has eventually 
helped to increase the healthcare quality.[4] These policies 
clearly showed the eagerness of the government to provide 
better healthcare infrastructure with better medical devices 
and facilities.
WHY WE REQUIRE HARMONIZATION?
A central function of any democratic government is to 
promote the economic and social well-being of its people. 
Governments seek to meet that objective in a wide variety 
of ways and in line with this, the regulation is an important 
tool that has helped governments make impressive gains 
in attaining desirable public policy goals. But where 
regulations impede innovation or create unnecessary 
barriers to trade, investment, and economic efficiency; 
duplication between regulatory authorities and different 
layers of government, and even among governments of 
different countries; the influence of vested interests seeking 
protection from competition; and regulations that are 
outdated or poorly designed to achieve their intended policy 
goals are all part of the problem. It is difficult to measure 
the precise cost of failure to harmonize the regulation, but 
it can be substantial. Delay heightens the cost of change in 
many cases. The hidden costs of inefficient regulation are 
increasing as the competition in global markets intensifies. 
In sectors characterized by rapid technological change 
or high international mobility, failure to harmonize the 
regulation can disadvantage entire economic sectors or 
lead to pressure for costly supports and protectionist 
policies. All governments have a continuing responsibility 
to review their own regulations and regulatory structures 
and processes to ensure that they promote efficiently and 
effectively the economic and social well-being of their 
people. A growing number of countries have embarked in 
recent years on ambitious programmes to reduce regulatory 
burdens and improve the quality and cost-effectiveness of 
regulations that remain. The difficulties and complexities 
have sometimes been greater than expected and there 
are many questions about the risks and costs of further 
reform, as well as continued strong opposition from 
vested interests.[5] Yet much has been learned about how to 
harmonize the regulation, and it is clear that the risks and 
difficulties of not harmonizing are often greater.
A fundamental objective of regulatory harmonization 
is to improve the efficiency of national economies and 
their ability to adapt to change and to remain competitive. 
Harmonization that sharpens competitive pressures 
provides powerful incentives to firms to become more 
efficient, innovative, and competitive. These improvements 
can boost the productivity of entire industries and often 
bring sharp and swift price reductions and improvements 
in the quality and range of products and services, to the 
benefit of consumers and user industries. For example, the 
European market alone, by promoting competition and 
replacing many separate national requirements by single 
Europe wide requirements, is estimated to have increased 
the European GDP by up to 1.5% between 1987 and 
1993.[5] Harmonization that reduces business burdens and 
increases the transparency of regulatory regimes supports 
entrepreneurship, market entry, and economic growth that, 
in turn, should produce high-paying, high-quality jobs. 
Harmonization that reduces “red tape” and paperwork 
burdens for ordinary citizens — particularly in their role 
as taxpayers — frees up valuable time and individual 
initiative. In turn, more productive, innovative, and flexible 
economies are in a better position to meet other public 
interests and to help governments deal with issues such 
as social cohesion, environmental quality, and the rapid 
aging of populations.
NEED FOR HARMONIZATION
After the era of liberalization and then globalization, 
international boundaries are no longer obstacles and the 
whole world is called as a Global Village. In addition if we 
concentrate little on changes in the world economy then we 
find that there is a slower growth in USA, EU, and Japan 
and robust growth in developing countries with sustained 
and rapid growth in China and India continuing their higher 
growth potential. There is a desire of developing economies 
to ensure safety and performance of products brought to 
their markets. Due to the competitive market, the pricing 
pressure is gradually increasing. Overall, the market trends 
prompt the need for a better operating model because 104   J Young Pharm Vol 2 / No 1
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traditional lines of business, technology, and competition are 
blurring; the definition of customer is changing; regulatory 
scrutiny is increasing; because of increasing regulatory 
pressure on governments and industry with scarcity of 
resources both human and financial; international market is 
big and getting bigger; and demographic trends are driving 
fundamental changes in the global economy.[5] 
In our perspective, we can say that there is “internationalization” 
of the medical technology industry. There is global 
research and development, global clinical trials, global 
product introduction, multiple manufacturing location, 
etc. worldwide. Increasing worldwide recognition of 
medical device as a major future of healthcare industry 
sector - providing benefits for national independence 
for the medical device sector - is reflected in recent 
policy declaration by state as well as central government. 
For potential investors, however, global expansion of 
medical device continues to be viewed primarily through 
a financial and economic prism that focuses particularly 
on medical device’s competitiveness vis-à-vis other 
sectors of health industry such as pharmaceuticals and 
biologics. A major factor in this equation is the potential 
for economies of scale achieved by developing new 
medical devices in series. Currently, national variation in 
safety regulation presents an obstacle to internationally 
standardized regulation, which would faster these 
economies. The achievement of harmonization of medical 
device regulatory standard has overcome this obstacle, 
facilitating the emergence of a global market that offers a 
choice number of medical devices that are recognized by 
regulators as safe and technologically mature.
Adding to these, every regulatory body, while framing the 
regulation, has mainly two objectives that it wants to fulfill: 
First a timely and effective premarket review and second 
consistent and appropriate postmarket regulation. This can 
only be achieved when there is standardized regulation for 
medical devices which is internationally accepted.[5] This 
means that the whole process of premarket evaluation and/or 
postmarket surveillance takes as less time as possible because 
it saves time as well as investment to market the product that 
is prime requirement in the view of manufacturers. 
There are various segments that are benefitted by this 
harmonization and we call it as harmonized regulation 
of medical devices. If we talk about industry’s need, 
then this approach will eliminate redundant requirements 
that do not contribute to safety. As far as regulators are 
concerned, they need the harmonized regulation because 
it reduces redundant reviews, creates an opportunity to 
share information on product safety, and results in a more 
efficient regulatory regime. The net result is improved trade 
in medical devices and safer products for consumers.
The harmonization of medical device regulation is 
needed to:[6]
(1) Reduce the time to market the product by:
(a) Eliminating  undue  or  perhaps  unjustified 
country-specific requirements
(b) Providing transparent requirements which simplifies 
market access and expedites patients’ access to new 
and innovative technologies.
(2) Reduce the cost to market the product by:
(a) Establishing uniform international regulatory 
system and requirements
(b) Reducing unwarranted, often contradictory 
regulatory requirements and redundant applications 
of similar requirements that can lead to different 
product definitions in various geographies, further 
complicating follow-up and comparison of data 
on safety issues which reduces resources and the 
complexity needed to meet local requirements and 
improves the utilization of already stretched and 
limited human and financial resources.
(3) Improve government efficiency by:
(a) Facilitating cooperation among regulators and the 
industry in conducting regulatory activities such 
as common audits, submission requirements, PMS 
procedures, acceptance and use of international 
standards, exchange of safety information which 
can be leveraged on experience gained over time.
(4) Facilitate trade and expand market access by:
(a) Creating common requirements for addressing 
the product life cycle (development, manufacture, 
placing on market, postmarket surveillance) which 
reduces the burden, complexity, and unpredictability 
for gaining market clearance.
(5) Enhancement of public health protection by:
(a) Establishing common and transparent premarket 
evaluation, postmarket surveillance, uniform quality 
system with similar audit criteria, and common 
clinical safety performance.
This provides increased product safety and efficacy thereby 
promoting public health and ensuring consumer confidence.
CHALLENGES AND RISKS OF NOT HARMONIZING 
MEDICAL DEVICE REGULATION IN ASIA
The medical device industry growth in Asia is predicted to 
be extremely strong in the coming years. More technologies 
and products are being exported from Asia to the rest 
of the world. Asia is diverse in many respects and with it J Young Pharm Vol 2 / No 1  105
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come the various challenges to harmonizing medical device 
regulations. A regulatory reform that enhances competition 
and reduces regulatory costs can boost efficiency, bring 
down prices, stimulate innovation, and help improve 
the ability of economies to adapt to change and remain 
competitive. Properly done, a regulatory reform can also 
help governments promote other important policy goals, 
such as environmental quality, health, and safety. Finally, 
country experience convinces us that the unavoidable 
disruptions which can accompany the reform can be 
addressed by complementary policies and actions.
Despite this, it is clear that many international organizations 
like GHTF, AHWP, APEC, ASEAN, etc. have made 
progress in developing standards and policies for the 
regulation of medical devices, particularly among their 
member nations. There is evidence of coordinated 
efforts such as the NCA Report Exchange Program, 
which has increased communication and dissemination of 
information between NCAs. However, it is questionable 
whether such progress has really resulted in any significant 
level of global harmonization. For example, 15 years after 
GHTF’s inception, its membership has not expanded 
beyond the original founding nations, and considering 
GHTF’s recognition of a “surging” increase in medical 
device manufacturing in nonmember nations, the scope 
and applicability of its harmonization policies is limited. 
Since the potential for medical devices manufactured 
outside member nations adhering to harmonized standard 
requirements is low, such harmonization efforts seem to 
be largely fruitless and it will be a long, slow road to global 
harmonization of medical device regulation.
One conclusion that emerges after reviewing the whole 
effort done by different organizations in different 
continents is that the most important ingredient for the 
successful harmonization of medical device regulation 
is the strength and consistency of support at the highest 
political level. Ministers have a direct role to play in 
assuring that strong political leadership will overcome 
vested interests in both public and private sectors which 
benefit from the status quo and resist beneficial change. 
But ministers and elected leaders cannot accomplish the 
necessary changes alone. Open dialog and communication 
is also an indispensable part of the process. It can 
strengthen the voices of those who support and will 
benefit from the harmonized guideline. Important allies 
in the harmonization process include businesses which 
will gain from low-cost, high-quality goods and service 
inputs; consumers; and employees and their representatives 
in fields in which job creation and wage growth are 
constrained by unnecessary regulatory restrictions.
If we talk about challenges for the harmonization of 
medical devices specifically, then we should consider that 
the following observations can be made:[6]
•  Diversity in culture, language, politics, economy, race, 
religion;
•  Differing regulatory capacity, expertise, infrastructure, 
finance;
•  Varied collection of regulatory systems, differences in 
philosophy;
•  Rising and varied expectation of medical technology;
•  Government restrictions like control over the price; 
subsidy reduction involvement is a considerable 
challenge for any reform; due to account deficit the 
government may try to exclude a health insurance 
scheme in a particular area where a large investment 
of money is required;
•  Local companies do not want to come under any 
regulatory body because they put him back to make 
unsafe devices;
•  Historical issues — retention of sovereignty, trust, 
and confidence in decision/assessments from various 
regulators;
•  Difficulties for stakeholders to reach consensus on 
harmonization efforts;
•  Overall complexity of products and the market place;
•  Sheer magnitude in the number of countries that are 
currently regulated, modifying regulations, developing 
new regulations;
•  Many countries have long established regulatory 
systems which are difficult to change;
•  Lack of trained manpower, lack of political commitment, 
and slow momentum in harmonizing fundamental 
issues such as definition, classification, nomenclature, 
and manufacturer.
According to the policy recommendation for reforms in 
regulation by OECD (Organization of Economic Co-
operation and Development), there are different kinds of 
challenges for harmonization of medical devices that are[5]
•  Adoption of a regulatory harmonization broad 
program at the political level that establishes clear 
objectives and framework for implementation;
•  Reviewing regulation systematically to ensure that it 
continues to meet the intended objectives efficiently 
and effectively;
•  Assurance that regulation and regulatory processes are 
transparent, nondiscriminatory, and efficiently applied;
•  Reform of the regulations of medical devices at a global 
level in all sectors to stimulate competition and eliminate 
them except where clear evidence demonstrates that they 
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•  Identification of important linkages with other policy 
objectives and develop policies to achieve those 
objectives in ways that support harmonization. 
Before discussing about risks of not harmonizing, I would 
like to introduce the words of Lao Tzu “If you don’t change 
the direction, then you may end up where you are heading,” 
which is self-explanatory that we must allow preexisting 
regulation of medical positive changes and of course this 
is also true with the devices which is country specific, i.e., 
not harmonized.
This means that we must harmonize the regulation for 
easy trafficking of devices throughout the world. If we 
concentrate particularly on India, then this becomes very 
important because:
•  There are challenges of complying with disparate 
international regulatory systems and requirements 
regardless of the fact where the manufacturing hub is 
located;
•  There are expending resources to deploy local 
infrastructure to access international markets;
•  Regulatory authorities have to identify and comply with 
different sets of regulation for each targeted country;
•  There are transparent and unified international 
regulatory systems to reduce time to market, i.e., 
seamless access.
So if we don’t harmonize the regulation, this will lead to:[7]
•  Continued and escalating divergence between statutory 
regulatory systems leading to:
(1) Incomplete regulation, lack of implementing 
guidelines,
(2) Confounding regulation in following areas: 
(i)  Premarket evaluation (product classification, 
submissions, review, clinical protocols/
expectations, approval times)
(ii) Use of standards
(iii) Quality system requirements
(iv) Audits
(v) Vigilance: Definition, reporting, decision making,
(3) Lack of or inability to leverage information sharing,
(4) Lack of common requirements/processes for 
handling new, innovative devices;
•  Unpredictable environment due to the development 
of unclear regulation and control of the system;
•  Continued rise in the cost of medical therapies;
•  Uneven playing field leading to market access barriers;
•  Delayed or absent access to innovative technology;
•  Reduced, impaired access to important, life-saving 
devices.
CONCLUSION
After considering all of the above-mentioned issues, we 
can say that when harmonized regulation of medical device 
comes into existence and consequently a uniform adoption 
of harmonized regulation takes place, then there is availability 
of quality product. People get assured about its effectiveness 
and safety. The small firms which produce fake and/or 
ineffective devices become obsolete from the market. These 
harmonized guidelines lead to the export-import of the 
product with less restriction worldwide and in other words 
we can say that there is a seamless access to the innovative 
medical device. But all of the above findings require a 
comprehensive research, meetings in order to exchange 
views and ideas of experts, gathering thoughts of legendry 
institutions, healthcare professionals and stakeholders, and 
definitely sharing the value with well-reputed healthcare 
firms. If all these things that we are considering above go 
in the right direction then we must configure a harmonized 
regulation for medical devices fulfilling the requirement of 
global standards. This all lead the Indian market with all of 
the above and the Vision-20 must be achieved.
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